How effective is Dawnzera (donidalorsen) in treating angioedema?

Dawnzera (donidalorsen) is a preventive treatment designed to prevent attacks of hereditary angioedema (HAE). On August 21, 2025, Dawnzera was approved by the U.S. Food and Drug Administration (FDA), becoming the first and only RNA-targeted preventive treatment for HAE. This approval marks an important milestone in the treatment of HAE and provides patients with new hope and options.

Dawnzera's therapeutic effects are significant and long-lasting, and it works by targeting plasma prekallikrein (PKK). PKK is a key protein involved in activating inflammatory mediators related to acute attacks of HAE, especially the production of bradykinin. By reducing the production of PKK, Dawnzera effectively reduces the incidence of HAE and helps patients achieve long-term disease control. Clinical trial results show that the use of Dawnzera can not only significantly reduce the frequency of HAE attacks, but also reduce the severity of attacks and improve patients' quality of life.

In theOASIS-HAE study, Dawnzera was administered as a subcutaneous autoinjection at a dose of 80 mg every 4 weeks and compared with placebo. Study results showed that Dawnzera Q4W significantly reduced the monthly HAE attack rate by 81% over 24 weeks compared with the placebo group. This data fully demonstrates the effectiveness of Dawnzera in actual clinical applications. In addition, when measured from the second dose, the average incidence rate was further reduced by 87%, and the reduction in moderate to severe HAE episodes was nearly 90%. These results not only reflect Dawnzera's excellent performance in reducing seizure frequency, but also provide a reliable basis for patients' condition management.

Dawnzera's dosing schedule is flexible and patients can choose to dose it every 4 weeks or every 8 weeks according to their individual needs. This long-lasting dosing interval design allows patients to reduce the burden of frequent medical visits during treatment and facilitates self-management in daily life. At the same time, Dawnzera's subcutaneous delivery method also makes the injection process simple and easy, suitable for patients to self-inject at home.

Reference materials:https://www.drugs.com/dawnzera.html